InsiderSignalSign in

← Insider buys

NKTX

Nkarta, Inc. · Healthcare

Insiders sold $54K of Nkarta, Inc. in the last 12 months and bought none

$0Bought, 12 mo

$54KSold, 12 mo

$128.9MMarket cap

NKTX over the last year

No insider buys filed in this year

NKTX after insider buys

3 months after each buy, from the first price a copier could get.

2 buys have 3 months of prices so far. A record shows here at 3.

Every filing

34 insider filings since 2021, newest first

Paul J Hastings · CEO

$54K−6.0%Jan 20

Alicia J. Hager · General Counsel

$27K−3.0%Jul 18

Ralph Brandenberger · Chief Technical Officer

$105K−9.0%Mar 5

James Trager · Chief Scientific Officer

$50K−3.0%Feb 14

David Shook · Chief Medical Officer

$31K−3.0%Jan 18

James Trager · Chief Scientific Officer

$40K−3.0%Jan 18

Paul J Hastings · CEO

$85K−2.0%Jan 18

Alicia J. Hager · General Counsel

$40K−4.0%Jan 18

Paul J Hastings · CEO

$311K−9.0%Sep 30

Paul J Hastings · CEO

$80K−2.0%Sep 22

James Trager · Chief Scientific Officer

$88K−7.0%Aug 17

Ralph Brandenberger · Chief Technical Officer

$194K−59.0%Aug 17

Nadir Mahmood · Insider

$135K−14.0%Aug 17

Ralph Brandenberger · Chief Technical Officer

$180K−60.0%Aug 10

Nadir Mahmood · Insider

$115K−14.0%Aug 10

Ralph Brandenberger · Chief Technical Officer

$40K−28.0%Jul 26

Nadir Mahmood · Insider

$100K−14.0%Jul 26

Ralph Brandenberger · SVP, Technical Operations

$62K−44.0%Jun 7

Simeon George · Director

$20.0M−200.0%Apr 29

Ra Capital Management, L.P. · Director and 10% owner

$33.0M+39.0%Apr 28

Ralph Brandenberger · SVP, Technical Operations

$65K−100.0%Dec 3

Paul J Hastings · CEO

$231K−4.0%Oct 1

Ralph Brandenberger · Insider

$133K−100.0%Sep 2

Kanya Rajangam · Chief Medical Officer

$373K−100.0%Aug 9

James Trager · Chief Scientific Officer

$114K−8.0%Aug 4

Nadir Mahmood · Insider

$206K−19.0%Jul 6

Paul J Hastings · CEO

$226K−4.0%Jun 23

Ralph Brandenberger · Insider

$101K−100.0%Jun 4

Nadir Mahmood · Insider

$81K−10.0%May 12

James Trager · Chief Scientific Officer

$114K−7.0%May 5

Nadir Mahmood · Insider

$114K−10.0%Apr 2

Paul J Hastings · CEO

$523K−7.0%Apr 1

James Trager · Chief Scientific Officer

$251K−12.0%Feb 3

Nadir Mahmood · Insider

$267K−15.0%Jan 26

About Nkarta, Inc.

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.